Videos

Dipti Patel-Donnelly, MD, discusses the gaps between academic centers and community oncology regarding treatments for hematologic malignancies.

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

BCG-unresponsive NMIBC requires vigilant surveillance during new treatments to avoid missing signs of progression and avoid delaying cystectomy, which remains the best chance for cure if intravesical therapies are failing.

An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.

Jennifer A. Woyach, MD, discusses background and updated findings from the phase 1/2 BRUIN study of pirtobrutinib for the treatment of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior treatment with a covalent Bruton tyrosine kinase inhibitor.

Anita Kumar, MD, discusses findings from the phase 2 study of zanubrutinib, obinutuzumab, and venetoclax in TP53-mutant mantle cell lymphoma presented at ASH 2023.

Sara A. Hurvitz, MD, discusses some of the current important questions for the field of HER2-positive breast cancer now and highlights which of these unanswered questions she hopes are addressed soon.

Brea C. Lipe, MD, discusses the evolving landscape of multiple myeloma treatment, highlighting the current abundance of drugs and the challenges associated with optimizing their use.

Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.

Virginia Kaklamani, MD, presents the case of a 56-year-old woman with HR+/HER2- metastatic breast cancer and visceral metastases.

Paolo Tarantino, MD, discusses what to know about the real-world findings from the RELIEVE study which were presented at the 2023 San Antonio Breast Cancer Symposium.

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.

Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.

Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.

Douglas W. Sborov, MD, MS, provides a summary of the key details of the 54-year-old patient's medical history and multiple myeloma diagnosis.

Other considerations between KRAS targeting treatments in patients with KRAS+ mutated NSCLC.

An overview of recognizing and managing common immune-related and systemic adverse events with immune checkpoint inhibitors, chemotherapy and KRAS targeted therapies in NSCLC.

Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.

An overview of the role of KRAS G12C inhibitors in the second line and beyond for KRAS G12C mutated NSCLCs after progression on platinum-based chemotherapy.

Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.

Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.

Background on KRAS mutations in lung adenocarcinoma, including the prevalence, prognosis, and challenges in treating patients with NSCLC.

Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Dr Garica-Manero provides a brief overview of the current treatment paradigm for lower-risk MDS as well as discussing some unmet needs.

Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.

Sandip P. Patel, MD, offers advice to fellow oncologists and highlights unmet needs and future directions in the treatment of patients with non–small cell lung cancer.